From shaping care guidelines in the Netherlands to tackling gene therapy challenges at the MDA Summit, Cure CMD is driving progress in research and care. Join us at the 2025 SciFam Conference this August in Philadelphia—registration is open!

We are honored to support groundbreaking discoveries related to LMNA-CMD.

We are honored to support groundbreaking discoveries related to Dystroglycanopathy.

We are honored to support groundbreaking discoveries related to LAMA2-Related Dystrophy.

The MAGIC research team welcomes iMM to the consortium to add a cellular perspective to muscle-on-chip technologies

We are honored to support groundbreaking discoveries related to SELENON-Related Disorders.

Explore an in-depth interview with Gustavo Dziewczapolski, Doctor in Neuropharmacology and Scientific Director of Cure CMD. Gain insights in

Cure CMD’s Scientific Director, Dr. Gustavo Dziewczapolski, provides a recap of his attendance at the 8th International Myology Congress in

We are honored to support groundbreaking discoveries in Collagen 6-Related Dystrophies (COL6-RD).

A “Triad” of patient advocacy organizations for ultra-rare congenital muscular diseases, Cure CMD (Congenital Muscular Dystrophy), A...

Cure CMD has achieved significant impact in its first nine years as the only nonprofit organization in the U.S. dedicated specifically to...

The last week of December 2016 finds us with the first and second ever FDA-approved treatments for two groups of affected individuals...

Dear CMD Community, I am delighted to join Cure CMD as the new Scientific Director. I am eager to build on the legacy of strong...